



The Speculative Turn in IVF 




   
Contemporary IVF is undergoing a speculative turn, which is characterised by an increasing 
number of tests and treatments that are future-oriented, risk-focused and speculative in nature. 
Beyond a treatment for current experiences of infertility, IVF is increasingly oriented towards 
the pre-emptive and proactive treatment of future infertility. This proactive approach is 
reflected in the growing popularity of cryopreservation technologies—particularly oocyte 
cryopreservation (OC), or egg freezing—both in existing fertility clinics and in new 
specialised start-ups. In the US, fertility companies provide and heavily market egg freezing 
as a widely-indicated means of counteracting age-related fertility decline. Thus changing the 
indication for fertility treatment, predictive technologies for fertility testing have also become 
an integral part of a pro-active fertility management. Major IVF clinics offer fertility check-
ups—so-called ‘fertility MOTs’—and a growing number of start-ups specialise in data-driven 
testing innovations, which use reproductive health data and predictive analytics to offer 
personalised estimations of future reproductive chances. Investments in these preservation 
and prediction technologies reflect how a speculative orientation to the futurity of fertility is 
increasingly central to contemporary IVF practices.  
In part, this speculative turn follows the emergence of new oocyte vitrification 
technologies which significantly improved the prospects for female fertility preservation 
(Kuwayama et al. 2005). Especially after the ASRM’s 2012 declaration that egg freezing was 
no longer considered “experimental”—and in spite of the Society’s less widely-quoted 
reservations about OC’s use to circumvent age-related infertility—egg freezing has rapidly 
gained in popularity and is now on offer in 97% of US IVF clinics (ASRM 2012; CDC 2018, 
22). Uniquely, egg freezing is both an infertility treatment for the fertile and a fertility 
treatment for the infertile. Younger, fertile women are freezing their eggs in preparation for 
future infertility, while frozen eggs enable the possibility of conception after the onset of age-
related infertility. Through this double movement, categories of fertility, infertility and what 
we may call “postfertility” are mobilised in new ways. This article addresses how processes 
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of financialisation are at the heart of this step-change in the ‘proactive’ recognition and 
treatment of future infertility in contemporary IVF.  
The speculative turn in assisted reproduction is also characterised by speculative 
investments in these technologies by investors, entrepreneurs, employers and patients alike. 
Although the relation between reproduction, cellular life and capital has been extensively 
theorised through concepts of biocapital, biovalue and bioeconomies (see Helmreich (2008) 
for an overview), the shifting power dynamics in the fertility sector resulting from large 
equity investments, increasing consolidation and the institutionalisation of financial 
instruments for IVF payment have received relatively little attention. While scholarship on 
egg freezing has addressed the neoliberal rationalities underlying ‘fertility preservation,’ this 
paper argues that processes of financialisation are equally crucial to understand the rising 
popularity of egg freezing. It does so by focusing on the role of financialisation in 
establishing the infrastructures through which OC may be accessed and considers, by 
extension, how the recent emergence of egg freezing is re-organising reproductive healthcare 
more broadly.  
Focusing on egg freezing specifically, this article seeks to characterise the 
financialisation of fertility and its crucial role in shaping the contemporary IVF institutional 
landscape. I first develop a conceptual framework in dialogue with the literature on 
financialisation, biocapital and cellular life. Focusing on fertility, I subsequently describe the 
role of equity investments in the emergence of egg freezing start-ups and the concomitant 
expansion and consolidation of fertility services.1 I then describe how financial products such 
as subscription plans and insurance for egg freezing establish a dynamic between investment 
and indebtedness through which ongoing fertility is enacted and constituted. Drawing on 
Melinda Cooper’s and Sarah Blacker’s (2008; 2014) work on financialisation in regenerative 
and genomic medicine, I discuss how both the material conditions and the underlying logics 
of financialisation function as enabling conditions and interpretative frames for a reinvented, 
speculative and precarious notion of fertility and its futurities.  
The financial investments and broader commercial and clinical infrastructures constructed 
around the promise of fertility preservation, of course, do not determine specific experiences 
of egg freezing, but they nonetheless do play a key role in constructing the material realities 
that organise OC practices, thereby mainstreaming egg freezing across larger groups of 
                                                 
1 This study focuses specifically on the new equity-backed start-up companies specialised in egg 
freezing, rather than IVF clinics in general. Information about the amount of equity funding received 
by these companies is in the public domain and may be accessed through online databases such as 
Crunchbase. The paper draws on Vertommen’s genealogical method for analysing the “reproductive-
industrial complex” as well as Bal’s method of cultural analysis by reading key discursive objects that 
organise the marketisation of egg freezing—including online platforms, press releases and annual 
reports—in relation to a body of scholarship in reproductive studies and the political-economy of 
biotechnology (Vertommen 2017; Bal 2002).  
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potential patients, integrating egg freezing into future treatment plans and rationalising OC 
through new treatment logics that are changing what it means to be fertile in the 21st century. 
 
Financialisation, Fertility and Cryopreservation  
Dominant discourses of egg freezing—particularly so in the US context—align neatly with 
neoliberal rationalities by appealing to ideas about “self-responsibilization” for the 
ongoingness of fertility and maximization of one’s “human capital” through the enhancement 
of future reproductive potential (Brown 2015). The growing body of scholarship on egg 
freezing has addressed OC in relation to the neoliberal subject, who bears a heightened 
responsibility for reproductive ageing, and popular risk-focused discourses on fertility 
characterised by an “implicit injunction to stay informed [and] to live the future in the present 
body” (Van de Wiel 2015, 123). Carroll and Krolokke analyse egg freezing as an enactment 
of “responsible” reproductive citizenship that “anticipates coupledom” and genetic 
relatedness (2018). Rottenberg likewise reads egg freezing as symptomatic of a middle-class 
neoliberal governmentality based on smart self-investments for enhanced returns in the future, 
while Emily Jackson highlights the possibility of blame and retrospective regret as the 
flipside of this responsibilisation of one’s future fertility (2016; 2017).  
 In this article, I analyse how the widely-observed neoliberal rationality of OC is 
situated in the context of regimes of financialised capitalism that are instrumental in creating 
the emergent clinical and commercial infrastructures through which egg freezing has become 
accessible in the first place. The financial systems and logics underlying the organisation of 
the US fertility industry are key to understanding the current popularity of egg freezing and 
the neoliberal governmentalities it exemplifies.  
 Current egg freezing practices are positioned against the backdrop of what Fraser 
calls “regimes of globalizing, financialized capitalism” (2015, 167).2 In contrast to a postwar 
state-managed capitalism, financialised capitalism “authorizes finance capital to discipline 
states and publics in the immediate interests of private investors” (2018, 75). Fraser argues 
that financialised capitalism remakes the constitutive institutional separation of reproduction 
and production through a move from the Fordist family wage to the ideal of the two-earner 
family. This shift is accompanied by the “steep rise in the number of hours of paid work now 
                                                 
2 In keeping with the article’s focus, I read egg freezing in relation to financialised capitalism. The 
emergence of egg freezing technology and practice is not reducible to this context, but the result of a 
complex history starting with the birth of the first frozen-egg baby in 1986 and developed with the aid 
of private and public funding, in relation to various indications (oncological, age-related, ethical) and 
in a variety of regulatory climates, which may spur on egg freezing in response to restrictions on the 
use of embryos or incentives for a new commercially-viable treatment for reproductive ageing (Chen 
1986). For a more detailed discussion, see Martin (2010), Waldby (2019) and Van de Wiel 
(forthcoming).   
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required to support a household,” which effectively entails an obligation to “shift time and 
energies once devoted to reproduction to ‘productive’ (i.e. paid) work.” In light of these 
developments, Fraser contends egg freezing is symptomatic of a social organisation which 
requires “shoehorn[ing] social reproduction responsibilities into the interstices and crevices of 
lives that capital insists must be dedicated first and foremost to accumulation” (2018, 87). In 
this process, egg freezing not only functions as a resolution to this scarcity dynamic between 
production and reproduction, but also brings fertility itself into the realm of accumulation.  
Of course, from its very inception, fertility treatment has been closely aligned with 
capital accumulation and privatised healthcare. In the UK, where the first IVF baby was born 
and the first IVF clinic was founded in 1980 by the clinicians responsible for Louise Brown’s 
birth, the emergence of this new medical sector coincided with Margaret Thatcher’s rise to 
power. Marilyn Strathern has described the “enterprising up” of IVF in this context and Sarah 
Franklin has analysed IVF in relation to the “enterprise culture” of Thatcherism (1990; 1997). 
Gay Becker documented the embeddedness of IVF experiences in the ethos of the American 
Dream (Becker 2001, 39; Franklin 2013, 240). The neoliberal responsibilisation of future 
fertility with OC emerges in the wake of these histories of IVF.  
Yet egg freezing is also quintessentially a reproductive technology of the 
contemporary moment, in which a shift towards financialisation in the fertility sector—
particularly the largely private US sector—meets a speculative turn in IVF enabled by 
(cryo)preservation and prediction technologies. Financialisation here includes “changes in 
management ideology that increasingly orient firms to financial markets (i.e., ‘shareholder 
value’),” “the growing influence of financial products, [and] the extension of debts in 
underserved communities” (Krippner et al. 2017). To understand the phenomenon of egg 
freezing, then, we need to not only focus on clinicians and patients, but also on the firms and 
financiers that shape this part of the reproductive bioeconomy. This requires addressing not 
only the sale of commodities (e.g. revenues for goods and services), but also the financial 
value ascribed to egg freezing by the capital markets and their investments in fertility 
companies (Birch 2017, 472). What is at stake in this focus on financialisation in the fertility 
sector is not so much the fact of commercialisation, but rather the shift in power relations and 
the reconceptualisation of female fertility in the face of the changing financial dynamics that 
govern the industry and its viability.  
A small body of scholarship in critical political economy analyses the relation 
between financialisation and the biotechnology sector (Hogarth 2017, 253). This work draws 
attention to the way in which value is assigned on the basis of a speculative estimation of 
future profit when institutions operate according to a financialised logic (Blacker 2014, 127). 
The promise of future value--whether produced through future profit margins or future 
acquisitions and exits--can attract investment capital. In healthcare, financialisation has 
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resulted in the expansion of markets, the development of private insurance markets alongside 
public programs, a managerial focus on shareholder value and speculative “expansions, 
mergers, and acquisitions aimed at profit maximization and consolidating market advantage” 
(Mulligan 2015, 39).  
In Life as Surplus, Melinda Cooper theorises financialisation and bioeconomies in 
relation to stem cell technologies. Cooper describes how the encounter with the limits of 
industrial production in the 1970s recession opened up “new forms of production and 
accumulation” through financial investment in biotechnologies that relocated accumulation 
“beyond the limits of industrial production--in the new spaces opened up by molecular 
biology” (Cooper 2008, 22). She argues that the flooding of venture capital into biotech 
companies was a clear sign of how speculation had become “the driving force behind 
unprecedented levels of innovation, allowing whole industries to be financed on the mere 
hope of future profits”--particularly so in the biotech sector, where cellular life “bec[a]me 
intimately infused with the virtual temporality of speculation” (Cooper 2008, 96). In a similar 
vein, Philip Mirowski characterises the “biotech firm” as a “financial artifact” because these 
firms “are not primarily configured as technoscientific organizations—that is, as producers of 
technoscience or technoscientific products—but, instead as financial organizations” because 
most biotechs never produce a drug or final product (qtd. in Birch 2017, 464–65). Instead 
they reflect the “promissory character of contemporary capitalism” and the way in which “the 
promissory is transformed into the real and the role of VCs, market analysts and public 
exchanges in this process” (Martin qtd. in Hogarth 2017, 252–53). Yet while the financialised 
biotechnology sector “has not lived up to expectations” either financially or 
technoscientifically (Birch 2017, 471), the fertility industry is a biomedical sector that does 
show both financial and clinical returns, through which trends of financialisation and its 
relation to cellular life may be analysed differently.  
Theorising the relation between the biological and the financial, Cooper argues that 
the growth potential materialised in the stem cells’ generativity matches the growth drive of 
financialised capitalism. Following this work, this article explores how cellular 
cryopreservability likewise “becomes annexed within capitalist processes of accumulation” 
(2008, 19). It draws attention to the growing importance of fertility--to be distinguished from 
reproduction--within the accumulation strategies of the US IVF sector, focusing particularly 
on the relation between the accumulation of reproductive time and the accumulation of capital 
through OC. This article thus explores the relation between cryopreservation and 
financialisation in the new forms of indebtedness, financing and investment co-emerging with 






Equity for Cryo-eggs 
The increasing popularity of egg freezing is situated in a global fertility sector that has 
experienced consistent growth and is projected to continue expanding to an estimated $36 
billion by 2026 at an annual growth rate of over 10% (GVR 2019).3 In keeping with this 
trend, the total number of IVF cycles in the US has steadily grown every consecutive year 
(see figures). Although egg freezing only accounts for a small percentage of US IVF cycles—
only about 4% are performed for oocyte banking even though the procedure is on offer in 
97% of clinics—this technology has received widespread attention in popular media and 
academic scholarship (SART 2019; CDC 2018). In spite of these small—albeit rapidly 
growing—numbers of women freezing their eggs, the promise of cryopreserving female 
fertility has also attracted investors’ interest. Since 2016, millions of dollars of private equity 
(PE) and venture capital (VC) have been invested in egg freezing businesses, which 
materialize the promise of egg freezing as a growth technology that may be targeted at a wide 
                                                 
3 Estimations of the IVF market size vary wildly and methods for determining these figures are not 
transparent. What is clear across different IVF market reports, however, is the ongoing growth and 
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group of younger, fertile women, who may or may not want to have children in the future--a 
far greater segment of the population than those currently accessing IVF.   
Buoyed by VC and PE investments, egg freezing-focused start-ups are emerging rapidly 
and are changing the landscape of US IVF. Prelude Fertility, for example, is one major new 
player focused on egg freezing, which was founded in 2016 with the aid of $200 million 
equity investment. Extend Fertility has operated for a decade through its network of IVF 
clinics and, in 2016, opened the world’s first egg-freezing only clinic in New York. This 
business is backed by private equity from North Peak Capital and received a further $15M in 
2019 from Regal Healthcare Capital Partners. Kindbody was founded in 2018 with $6.3M 
seed funding and describes itself as “the future of women’s health, fertility and wellness.” It 
brings egg freezing to the streets of urban centres with yellow “fertility vans,” or “boutique 
mobile locations,” which offer information on egg freezing and on-site fertility testing 
(Kindbody 2019).  In 2017, embryologist Colleen Wagner Coughlin founded Ova Egg 
Freezing in Chicago as part of the four business entities of which she is the sole owner: 
Gamete Resources, Ova Institute, Cryovault and Egg Bank Foundation (Ditkowsky 2018). 
Ova Egg Freezing is a member of the California Cryobank Donor Egg Bank USA Network—
a major cryopreservation company that combines sperm, egg and cord blood banking after a 
massive merger and acquisition deal worth an estimated $1 billion by San Francisco-based 
private equity firm GI Partners (Ova 2018; Ditkowsky 2018).   
Beyond clinical services, some of the major new egg freezing start-ups offer financial 
products. The most high-profile company is Progyny, which sells fertility benefits covering 
egg freezing to employers. This fertility insurance was at the heart of an international media 
hype when Apple and Facebook began offering egg freezing benefits in 2014; since then, a 
growing number of Fortune 500 companies have adopted fertility insurance packages. 
Progyny secured almost $100 million in equity to grow its corporate fertility benefit business, 
a process which has been aided by a strategic alliance with Mercer, the world’s largest HR 
company (Lee 2016; Crunchbase 2019b).4 Although growth figures are not public, in 2018 
Progyny was named #3 on Crain’s Fast 50 List, which records the fastest-growing companies 
in New York based on growth in revenue in 2014-2017; listed companies have an average 
three-year growth rate of 2082%, so as the third Progyny should be well above that (Yang 
2018). Carrot Fertility is a smaller company that secured $3.7 seed funding to provide fertility 
health benefits and a digital platform to employers. Future Family received $114M in venture 
capital and debt financing to offer subscription plans for egg freezing and other fertility 
                                                 
4 These fertility benefits are particularly popular in the tech industry. Companies who confirmed they 
offer egg freezing benefits to female staff and employees’ spouses include Facebook, Apple, Google, 
Uber, Yahoo, Netflix, Snapchat, Intel, eBay, Time Warner, Salesforce, LinkedIn and Spotify (Kerr 




treatments (Crunchbase 2019a). Symptomatic of the financialisation of fertility, the funding 
attracted for these companies highlight the significance of financial products in the 
mainstreaming of US egg freezing.   
 
Collectively, these new egg freezing companies have a widespread reach; they manage 
relations with nation-wide networks of fertility clinics, manage influential online platforms 
and its innovations receive widespread media and academic commentary. The emergence of 
these for-profit egg freezing ventures is situated in the context of the US capital market, 
which is much larger than its European rivals; US start-ups therefore enjoy some relative 
advantage when looking for capital (Hogarth and Salter 2010). Reflecting the prominence of 
financialisation in the wider US economy, there has been a steady growth in US equity 
investments over the last years; 2018 was an all-time high with investments totalling $130.39 
billion, a 50% increase from the previous year, and breaking the record set during the dot-
com bubble in 2000. The San Francisco Bay area, including Silicon Valley, was home to 61% 
of all capital invested into US companies, displaying “by far the most extreme regional 
concentration ever seen,” and followed by the New York area (Dow Jones 2019, 2–3). 
Progyny’s investors, Future Family, Carrot Fertility, and of course California Cryobank are 
all based in the Bay Area, with New York being home to Prelude’s main investor Lee Equity 
and the headquarters of Progyny and Kindbody.  
Rather than simply providing the means for their emergence, the significant 
investment capital poured into egg freezing companies propels a much broader transformation 
in assisted reproduction. Birch and Tyfield describe the biotechnology sector as “underpinned 
by a rentier regime in which financial asset values are more important than revenues from the 
sale of biotechnology commodities” (2013, 322). In other words, key is not primarily the 
amount of revenue the company generates, but the (speculative) value of the company itself, 
based on its potential for future growth. The significant capital investment in egg freezing 
companies points to a valuation of their potential for future growth. These financial 
investments thus at once enable the current emergence of new egg freezing enterprises, signal 
the valuation of the promissory value of OC and materialise the speculation of further growth 
of this practice in the foreseeable future.  
The private equity investments in egg freezing companies, then, point not simply to 
the capital market’s interest in the profit that may be generated from (more) women freezing 
their eggs. Rather, I will argue it reflects a more ambitious vision that positions 
cryopreservation at the heart of a step-change from reproduction to fertility in contemporary 
IVF. As Stuart Hogarth has argued in this journal, the ongoing growth of US private equity 
has led to a new model of business development, which relies on securing equity investment 
by presenting not simply a convincing business model, but a compelling vision for creating 
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value that is by necessity futural and speculative in nature—and which aligns with the 
investment culture organising relevant capital markets. For example, Hogarth argues that the 
investment culture of Silicon Valley is organised by the ideal of “disruptive innovation,” 
which is characterised by “a compelling vision of socially beneficial market transformation 
communicated by a passionate CEO, a belief in the transformative power of information 
technology” and “the ambition for global growth and market dominance” (2017, 256–58). By 
zooming in on the case of Prelude Fertility, we can consider the discursive, financial and 
infrastructural dimensions of equity-backed egg freezing enterprises and the ‘disruptive’ 
visions of speculative fertility that propel them.  
 
Prelude and Speculative Fertility 
The largest recent OC investment was $200 million committed to Prelude Fertility, an 
ambitious fertility company founded in 2016 that primarily focuses on egg freezing. Its CEO, 
Martin Varsavsky, is a serial entrepreneur specialised in real estate and cloud computing. 
FON, self-reportedly the world’s largest Wi-Fi network with 21 million hotspots across the 
globe, was one of his enterprises; Prelude Fertility is his seventh, and his first time branching 
out to the fertility sector. Varsavsky partnered with Lee Equity to acquire RBA IVF clinics 
and My Egg Bank, one of the largest US egg banks, to form Prelude Fertility (Dorbian 2016). 
With enough equity funding to acquire numerous existing IVF clinics, Prelude became the 
second largest US fertility company in its first year. Although 86% of US IVF clinics perform 
less than 1000 cycles annually, Prelude did over 10.000:   
 
1. IntegraMed Fertility (including Shady Grove Fertility): 38,071 cycles.   
 
2. Prelude Fertility: 10,740 cycles.  
 
3. RMANJ: 8,474 cycles. (Dresner Partners 2018) 
 
RMANJ is almost two decades old and Shady Grove Fertility was founded 25 years ago by 
three physicians in a small Maryland office who claim never to have had “a master plan for 
SGF to expand as it has” (Cunningham 2017). Although Prelude’s cycles represent the 
activity of existing, acquired IVF clinics, this company reflects the ‘disruptive’ effects of 
private equity and an experienced entrepreneur who is an outsider to IVF, but certainly does 
have a master plan for fertility.  
 Exemplifying Hogarth’s characteristic of a “charismatic CEO with a vision,” 
Varsawsky’s plan revolves around cryopreservation as a means to mainstream infertility 
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treatment. Marketing Prelude as a “fertility company” rather than an infertility clinic, 
Varsavsky presents the so-called ‘Prelude Method,’ a treatment package that combines 
cryopreservation, IVF and embryo genetic screening, as “a complementary strategy to starting 
a family by having sex”: 
 
As opposed to people who solely rely on sex to make babies, people who rely on both 
sex and Prelude have a much greater chance of achieving their parental goals of 
having healthy babies when they are ready. Prelude uses the technology available to 
infertile people, on fertile people. At Prelude we believe that something as important 
as having […] a healthy baby, should not be left to chance. (Varsavsky 2016) 
Blurring distinctions between those who do and don’t need fertility treatment, the Prelude 
Method echoes Sunder Rajan’s description of a parallel phenomenon in postgenomics: “a 
reconfiguration of subject categories away from normality and pathology and toward 
variability and risk, thereby placing every individual within a probability calculus as a 
potential target for therapeutic intervention” (2006, 167). Similarly, the Prelude Method both 
expands the target population of IVF to fertile people and expands the IVF cycle to include 
embryo screening technologies, thereby providing two axes of growth. Moreover, unlike the 
potential birth of a baby after an IVF cycle, egg freezing does not have an equally clear 
endpoint for marking reproductive success. The potential for repeat cycles to accumulate 
more cryo-eggs for further fertility assurance presents another rationality for growth.  
Varsavsky’s vision of fertility care reflects a belief in the transformative power of 
technology—another characteristic of disruptive innovation (Hogarth 2017, 258). The belief 
that reproductive technologies can ensure that everyone can “have a healthy baby when [they] 
are ready” aligns with the vision that drove 23andme, the influential genetic testing company 
that started out with a similar amount of capital investment (Prelude Fertility 2017a). Its 
founder Anna Wojcicki said: “my goal isn’t to just minimize the chance of getting sick. I 
want to live a healthy life at 100” (Hogarth 2017, 259). The vision of healthy life extension 
by disrupting healthcare with genetic testing matches a vision of healthy reproductive life 
extension by disrupting fertility with (cryo)preservation and predictive technologies.  
This approach to fertility extension later in life is matched with a model of proactive, 
technologised fertility risk management earlier in life. The notion that young women should 
be “proactive” in managing their fertility in the face of the progressive loss of their embodied 
eggs is at the core of several egg freezing companies’ missions. Prelude describes itself as “a 
comprehensive fertility company with a focus on providing proactive fertility care,” as 
reflected in its slogan: “It’s time to take charge of your fertility” (2017). Likewise, Extend 
Fertility presents itself as “the first service in the country to focus exclusively on women who 
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want to proactively preserve their fertility options” and Progyny as the “leading digital 
healthcare company combining data and science to provide the first end-to-end, proactive 
fertility solution for employers” (Extend Fertility 2017a; Bartasi 2016). The emphasis on 
proactive fertility care suggests a contradistinction with the existing—by implication 
reactive—model of IVF, in which people access treatment when they experience infertility or 
other barriers to reproduction. Instead, proactive fertility care requires active, technologised 
management earlier in life to ‘preserve options’ and maintain the possibility of having 
(biogenetically-related) children later on.  
Here speculative investment in the eggs’ freezability aligns with the promissory value 
of the future return—for patients, companies and investors alike. As promise becomes the 
“one fundamental of post-Fordist production,” which functions as a means to “anticipate and 
escape the possible ‘limit’ to its growth long before it has even actualized,” cryopreservation 
enables the temporal manipulation of cellular life to meet the speculative, futural orientation 
of a “finance-dominated regime of accumulation” (Cooper 2008, 23–24). A variation of the 
“double reproductive value” of stem cells (Franklin 2006), the freezable eggs here hold a 
double speculative value through the cryo-enabled promise of both a future financial return 
and a future return of fertility. 
Varsavsky’s vision for the potential future growth of his fertility company—and the 
concomitant financial value for investors—is thus coupled with a reconceptualisation of 
fertility that facilitates this future growth. Overcoming the “limits to production” inherent in a 
‘reactive’ model of IVF that relies only on the treatment of infertile people, the possibility of 
pre-emptively treating future infertility through cryopreservation broadens the target group, 
while the risk-avoidant Prelude Method allows for an expansion of each IVF cycle with 
additional genetic screening technologies.  
It is this vision of a widely-indicated, extendable fertility that held the promise of 
future growth for Lee Equity, Prelude’s investors. Meeting the “ambition for market 
dominance” characteristic of disruptive innovation (Hogarth 2017), Prelude used their equity 
investment to acquire a nationwide network of 31 IVF clinics sprawling the US (Dorbian 
2017; Beltran 2018; Ho 2017). While the US fertility industry is highly fragmented—75% of 
clinics account for less than 0.24% of total cycles—egg freezing companies are establishing 
nationwide networks for fertility preservation. Whether through acquisitions (Prelude), 
strategic alliances with clinics (Progyny) or combining brick-and-mortar with mobile clinics 
(Kindbody), each of these companies have a broad geographical reach. The business case for 
investing in speculative fertility thus directly affects the landscape of US IVF as the equity 
investments enable network formations that position egg freezing companies as parent or 
umbrella organisations.   
12 
 
In order to reach a new group of potential patients,consolidated OC companies can 
also centralise marketing budgets to reframe IVF as a tool for comprehensive, pro-active 
fertility management. A case in point, Prelude’s expansion through the acquisition of a 
growing number of clinics allows for the concentration of marketing efforts—and this is 
exactly what the investors had in mind. Lee Equity were interested in the growth potential of 
IVF, given the rising age of first-time mothers and the legalisation of same-sex marriage. Yet 
they also recognised fertility awareness as a means to broaden demand for IVF. Collins Ward, 
a partner at Lee Equity, says that the “biggest surprise” he encountered in the fertility industry 
is the “low awareness of fertility services.” So the investment in Prelude was coupled with the 
“significant costs” of a big marketing push intended to, in Ward’s words, “speak to younger 
patients and younger Americans who live in social and digital media.” It is this drive to 
“increase awareness” that bears the promise of “a sizable upside in years to come” by pro-
actively appealing to a new group of potential patients, who are themselves encouraged to be 
pro-active about fertility (qtd. in Robbins 2017). Now comprising a nation-wide network, 
Prelude’s mission “to educate a generation of women of childbearing age about their fertility” 
and its “commitment to improving fertility awareness, and providing a proactive approach to 
family building” has a widespread reach (Prelude Fertility 2017b). 
Prelude’s online platform reframes fertility in line with the company’s vision of 
mainstreaming pro-active fertility management. It shows beautiful yet relatable young adults 
against a splash of stylish colours. Confident smiles are enframed with statements such as 
 
Find that right person. Focus on your career. Finish your education. The age of your 
eggs (not you) is the number one cause of infertility. (Prelude Fertility 2017a) 
  
Prelude’s website contrasts with the visuals of babies that dominate the majority of IVF 
websites (Hawkins 2013). Although other reproductive technologies are also on offer, the 
homepage prominently features egg freezing with a carrousel of quotes:  
 
Stop the hands of the biological clock with Prelude  
 
It used to be that women had few options, but not anymore  
 
In keeping with these statements, Prelude’s slogan of “Options Preserved” echoes a vision 
that, as Strathern reminds us, has been there since the conception of IVF, when the idea that 





“NRTs are presented as opening up reproductive options, the vision of a biology 
under control, of families free to find their own form” (Strathern 1990, 3–4).  
  
Yet here the focus lies less on the option of having a child and more on the continuation of 
fertility—as a precondition for achieving relationship, career and reproductive goals. In the 
absence of (the desire for) a child, fertility instead refers to a state of having options and the 
particular relation to futurity that implies.  
Prelude’s invitation to ‘preserve your options’ is counterbalanced by downward 
graphs that signal embodied egg loss. This framing of embodied fertility as ever in decline 
reflects a “capitalist promise [that] is counterbalanced by willful deprivation, its plenitude of 
possible futures counteractualized as an impoverished, devastated present, always poised on 
the verge of depletion” (Cooper 2008, 20). While the time of the body and the scarcity of 
eggs are construed as constraints to “having options,” the cellular temporal manipulation of 
cryopreservation affords their continuation. 
 Beyond marketing, the fertility companies’ online platforms are also key instruments 
in managing widespread networks. These platforms connect participating network members 
and take on functions previously covered by the clinic. Ongoing medical and emotional 
support is offered through concierge services and wellness apps (Progyny, Future Family), 
which provide a centralised discursive framing of the ‘entire fertility journey.’ Kindbody 
takes this one step further through its patient portal, which provides the foundation for 
“building a centralized data platform, allowing for standardized decision-making, and 
building predictive protocols to define and scale best practices” (Kindbody 2018b). The 
equity-based egg freezing companies thus affect IVF’s broader infrastructure through 
acquisitions and network formation, the centralisation of marketing and patient support 
through online platforms and the adoption of cloud-based services that enable standardisation 
across the network.  
 
Financing Fertility 
As egg freezing infrastructures are thus expanding through financial investments, the 
resulting high stakes in increasing the number of women who freeze their eggs coincides with 
a shift towards interpellating younger potential patients to freeze now to take advantage of 
their “peak fertility.” The appeal to younger people, who typically have less access to the 
significant sums needed for egg freezing, is matched with financial products offered to 
broaden access to OC treatment, which represents another dimension of the financialisation of 
fertility. Prelude, Extend Fertility and Future Family present subscription plans for egg 
freezing with fixed payments of $99-$300/month, while Progyny and Carrot Fertility offer 
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egg freezing insurance to employers. This section discusses the major financial instruments 
adopted in the efforts to mainstream egg freezing and considers how they set up a dynamic of 
indebtedness and investment as part of contemporary cryopreservation practices.  
Reflecting the trend towards promoting earlier freezing, Kindbody spreads the word 
about egg freezing and fertility decline by driving its fertility van through the streets of urban 
centres and offering passersby free fertility education and fertility tests. In the pastel-coloured 
yellow van, printed statements in photo frames convey the rationale behind earlier freezing:  
 
You will never be as fertile as you are today.  
 
Coupled with the “facts” that “we are born with all the eggs we will ever have” and “the 
quantity and quality of eggs declines with age” these statements convey a temporal logic in 
which fertility is continually slipping away—a slippage that may be halted with OC: 
“freezing eggs is like freezing time” (Kindbody 2018a). In keeping with this logic, OVA Egg 
Freezing states:  
  
Your fertility is never going to be as young as it is today--so why wait? (2017) 
 
This emphasis on the ongoingness of fertility decline--and the suggested urgency of 
freezing eggs as early as possible--coincides with a push to market egg freezing to younger 
women. Prelude Fertility’s president Susan Herzberg, for example, states that egg freezing 
“used to resonate primarily with women in their late 30s,” but Prelude is “now targeting 
women in their 20s and early 30s” (Ferla 2018). The senior OVA nurse specialist and 
‘Bachelor’ reality TV winner Whitney Bischoff likewise asserts that “we really want to 
[reach] the younger crowd because that’s the best time to do it” (2015).5  
This trend is coupled with fertility financing plans that enable this approach to early 
freezing. As Emily Jackson writes,  
 
the representation of egg freezing as a responsible choice for all women who might 
want to have children in the future is at odds with […] its unaffordability for almost 
all women. (2017, 30)  
                                                 
5 Commenting on US egg freezing more broadly, the ASRM ethics committee notes that it is 
“concerned about […] the line between education of young women and inappropriately aggressive 
marketing to them.” They recommend that providers disclose clinic-specific statistics as well as the 
fact that medical benefits and harms of OC are not yet fully understood (ASRM 2018). In their analysis 
of the quality of information about social egg freezing on the websites of 147 US clinics, Avraham and 
colleagues found that the majority of websites did not follow the ASRM guidelines on OC and related 




Because younger women especially are less likely to be able to afford OC--costs average 
around $10.000/cycle--these marketing efforts are often paired with payment plans. Within a 
treatment rationale that promotes earlier freezing, it is better to freeze young eggs now and 
pay later, rather than save up and freeze older eggs. In this way, the capital investments in the 
promise of the expansion of egg freezing as a mainstream practice are complemented with 
additional revenue produced through financial instruments such as fertility loans and 
subscription plans. Consequently, broadening the target group for egg freezing can increase 
revenue by creating new norms and needs for both clinical and financial services.  
The distribution of consumer credit through clinics is widespread throughout the 
fertility industry. The average cost for an IVF cycle in the US was $13.048 and a recent 
survey showed almost all infertility physicians identified cost as the largest barrier to care 
(McLaughlin et al. 2018). Almost 50% of US fertility clinics mention credit on their websites, 
often through third-party fertility lenders, such as CapexMD, IntegraMed and Prosper 
(Hawkins 2009, 863; Jacoby 2009, 148). Reflecting a national context characterised by a fee-
for-service healthcare and higher treatment fees, 70% of women using fertility treatment in 
the US accrued debt. Almost half of these women incurred over $10.000 in debt and younger 
women (25-34) borrowed significantly more than their seniors (Market Cube 2015). Firms in 
the industry estimate fertility-related loans totalled about $4 billion in 2011 (Silver-Greenberg 
2012).  
Although the debt financing of IVF can expand access, legal scholars have raised 
concerns about the potential conflict of interest arising from arrangements between clinics 
and lenders, given the power and trust relation between doctors and patients and the potential 
financial incentives for prescribing both particular treatments and the means to finance them 
(Jacoby 2009; Hawkins 2009). So while they may be valuable to patients struggling to afford 
treatment, fertility loans may also change the dynamics between financial and reproductive 
decision making for patients and professionals alike. Nonetheless, as Melissa Jacoby asserts, 
fertility companies that wish to expand “must move beyond the elite to those of more-modest 
means. Specialty consumer credit could be a key ingredient to this expansion, particularly 
when partnered with other financial products” (2009, 170, 175).  
Similarly, the egg freezing companies’ encouragement of earlier freezing may also 
entail an invitation into a debt relation between patient and the fertility (financing) company. 
The creation of financing companies such as Future Family attests to the fact that the debt 
financing of egg freezing cycles functions as a revenue source in its own right. Companies 
such as Extend Fertility work with external lenders for their subscription plans, which charge 
between 7% and 22% interest rates and 1%-6% origination fees, depending on one’s credit 
score. In this way, the financial risk taken by clinics to recruit younger people with less 
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financial means is transferred to lenders, who subsequently pass this risk on to patients 
through varying rates and fees—in line with Lazzarato’s observation that financialised 
capitalism demands “that one take upon oneself the costs and risks externalized by [...] 
corporations” (2012, 51). In this process, value is created through a circular shifting of 
financial and reproductive risk: as patients shift the risk of future infertility to the clinic, 
clinics transfer the risk of nonpayment to lenders, who, in turn, move this risk to patients 
through differential rates and fees. In this dynamic exchange of reproductive and financial 
risk, fertility lending thus aligns companies’ capital accumulation with patients’ fertility 
accumulation through OC. By promoting both a proactive treatment rationale and fertility 
financing, this debt financing model of egg freezing creates value through a double temporal 
movement of anticipation and deferral; it combines treating future infertility in the present 
and paying for present treatment in the future.   
 
 
Lastly, besides fertility financing, fertility insurance is another financial product that 
is rapidly growing in popularity as a result of capital investments in cryopreservation. Having 
secured almost $100M in venture capital, market leader Progyny has a widespread reach with 
its online platforms, over 500 affiliated clinics and coverage of a purported 1 million people 
(CNBC 2018; Progyny 2019). Its fertility benefit streamlines egg freezing into an elaborate 
IVF package presented as “the first end-to-end proactive fertility solution for both large, self-
insured employers [and] today’s informed consumer looking to manage their reproductive 
health” (2016). Progyny presents its proactive fertility programme to employers as a means to 
improve return on investment (ROI) both by limiting costs for absenteeism and multiple 
pregnancies associated with ‘reactive’ IVF and by fostering a “family friendly” and 
innovative image (Abdou 2016). Progyny thus integrates proactive fertility management into 
the workplace by positioning OC as a tool for employees to self-invest in future fertility and a 
tool for employers to increase ROI. Significantly, by aligning the financial investment 






















employees, Progyny institutionalises a speculative approach to fertility, which positions egg 
freezing as the entry point into a long-term, highly-technologised, proactive fertility 




This article focuses on the remarkable emergence of egg freezing in the last decade and 
explores the ways in which processes of financialisation play a central role in the organisation 
of contemporary US IVF—and the widespread mainstreaming of OC in particular. Situated in 
a broader context of financialised capitalism, the growing popularity of egg freezing is 
propelled by large capital investments in cryopreservation in recent years. The growth 
potential of egg freezing as a widely-indicated treatment and the promissory nature of pro-
active fertility preservation align directly with the logic of “promissory capitalism” 
underlying equity investment markets (Hogarth 2017, 266). It is therefore not surprising that 
the niche of (oocyte) cryopreservation has been particularly successful in attracting finance 
capital and, consequently, egg freezing is now at the heart of a consolidating trend of the US 
fertility industry that is both reorganising the sector and changing the discursive construction 
of fertility through these growing enterprises.  
As became clear in the case of Prelude Fertility, equity-backed expansion, acquisition 
and consolidation strategies can subsume traditional IVF practices under the umbrella of 
growing egg freezing enterprises. Even when clinics are not directly acquired, the egg 
freezing companies have a widespread reach through marketing efforts directed at broader 
target groups and financial products that cover treatment costs by bundling egg freezing with 
other treatments. By bringing together payment, telemedicine care and fertility information, 
centralised online platforms moreover become key framing instruments for organising and 
promoting egg freezing treatment across nation-wide networks.  
The major egg freezing companies also offer financial products such as subscription 
and insurance plans. Subscription plans are presented as a means to democratise access to 
treatment, yet, in doing so, they set up a dynamic of investment and indebtedness in the 
process of preserving fertility. Characteristic of financialisation, this brings debt relations to 
the heart of assisted reproduction and sets up additional sources of OC-related revenue 
through financial instruments, while enabling more spending on treatment cycles. Fertility 
insurance displaces the promissory value and speculative investment associated with egg 
freezing to the level of the employer and thereby integrates the (financial) management of 
fertility into the realm of labour. Both subscription and insurance products streamline egg 
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freezing into a wider set of treatments, thereby adopting OC as a stepping stone into a longer-
term trajectory of proactive technologised fertility management.  
By means of the expansive growth and reach of fertility companies--through mergers 
and acquisitions, network formation, online marketing and financial products--egg freezing is 
thus changing the landscape of IVF. The financialisation of fertility, in this context, 
references the significant financial investments in a future in which ever more women freeze 
their eggs, the role of private equity and venture capital in establishing the clinical and 
commercial infrastructures through which egg freezing becomes accessible, the alignment of 
the financialised logics of the capital market and those underlying dominant treatment 
rationales and the role of financial products in shaping both the stories and the streamlining of 
fertility preservation. Together, these developments are indicative of a shift from reproduction 
to fertility in IVF, in which treatment need not necessarily be aimed at having a child in the 
face of infertility, but rather at the proactive management of a more speculative fertility 
throughout the life course. As a result, the introduction and financial backing of egg freezing 
presents not simply another reproductive option, but has instigated a step-change in IVF and 










Abdou, Jenna. 2016. How Progyny Is Modernizing Family Planning with CEO Gina 
Bartasi. 33 Voices. 
https://www.youtube.com/watch?v=y5YjDlfBlBs#t=462.808435. 
ASRM. 2018. “Planned Oocyte Cryopreservation for Women Seeking to Preserve 
Future Reproductive Potential: An Ethics Committee Opinion.” Fertility and 
Sterility 110 (6): 1022–28. https://doi.org/10.1016/j.fertnstert.2018.08.027. 
ASRM Office of Public Affairs. 2012. “ASRM Lifts ‘Experimental’ Label from 
Technique.” American Society for Reproductive Medicine. October 22, 2012. 
http://elireshefmd.com/fertility-experts-issue-new-report-on-egg-freezing-
asrm-lifts-experimental-label-from-technique/. 
Avraham, Sarit, Ronit Machtinger, Tal Cahan, Amit Sokolov, Catherine Racowsky, 
and Daniel S. Seidman. 2014. “What Is the Quality of Information on Social 
Oocyte Cryopreservation Provided by Websites of Society for Assisted 
Reproductive Technology Member Fertility Clinics?” Fertility and Sterility 
101 (1): 222–26. https://doi.org/10.1016/j.fertnstert.2013.09.008. 
Bal, Mieke. 2002. Travelling Concepts in the Humanities: A Rough Guide. Toronto, 
Buffalo, London: University of Toronto Press. 
Becker, Gay. 2001. The Elusive Embryo: How Women and Men Approach New 
Reproductive Technologies. Berkeley: University of California Press. 
Beltran, Luisa. 2018. “Prelude Fertility Buys Advanced Fertility Center of Chicago.” 
PE Hub (blog). March 6, 2018. https://www.pehub.com/2018/03/prelude-
fertility-buys-advanced-fertility-center-chicago/. 
Birch, Kean. 2017. “Rethinking Value in the Bio-Economy.” Science, Technology & 
Human Values 42 (3): 460–90. https://doi.org/10.1177/0162243916661633. 
Birch, Kean, and David Tyfield. 2013. “Theorizing the Bioeconomy Biovalue, 
Biocapital, Bioeconomics or . . . What?” Science, Technology & Human 
Values 38 (3): 299–327. https://doi.org/10.1177/0162243912442398. 
Bischoff, Whitney. 2015. “‘Bachelor’ Winner Whitney Bischoff: Why Freezing My 
Eggs at 27 Was One of the Best Decisions of My Life.” Splinter. July 2, 2015. 
https://splinternews.com/bachelor-winner-whitney-bischoff-why-freezing-my-
eggs-1793849303. 
Blacker, Sarah. 2014. “‘Your DNA Doesn’t Need to Be Your Destiny’: Colonialism, 
Public Health and the Financialization of Medicine.” TOPIA: Canadian 
Journal of Cultural Studies, no. 30–31. 
https://topia.journals.yorku.ca/index.php/topia/article/view/38424. 
Brown, Wendy. 2015. Undoing the Demos: Neoliberalism’s Stealth Revolution. New 
York: Zone Books - MIT. 
Carroll, Katherine, and Charlotte Kroløkke. 2018. “Freezing for Love: Enacting 
‘responsible’ Reproductive Citizenship through Egg Freezing.” Culture, 
Health & Sexuality 20 (9): 992–1005. 
https://doi.org/10.1080/13691058.2017.1404643. 
CDC. 2018. “Assisted Reproductive Technology: Fertility Clinic Success Rates 
Report 2016.” Atlanta: Centers for Disease Control and Prevention. 
ftp://ftp.cdc.gov/pub/Publications/art/ART-2016-Clinic-Report-Full.pdf. 
Chen, Christopher. 1986. “Pregnancy after Human Oocyte Cryopreservation.” The 
Lancet 327 (8486): 884–86. https://doi.org/10.1016/s0140-6736(86)90989-x. 
20 
 
CNBC. 2018. “Progyny 2018 Disruptor 50.” May 22, 2018. 
https://www.cnbc.com/2018/05/22/progyny-2018-disruptor-50.html. 
Cooper, Melinda E. 2008. Life As Surplus: Biotechnology and Capitalism in the 
Neoliberal Era. Seattle: University of Washington Press. 
Crunchbase. 2019a. “Future Family.” Crunchbase. 2019. 
https://www.crunchbase.com/organization/future-family. 




Cunningham, Caroline. 2017. “How a Tiny Maryland Practice Became the Biggest 
Fertility Clinic in the US.” Washingtonian (blog). May 1, 2017. 
https://www.washingtonian.com/2017/05/01/shady-grove-fertility-started-
tiny-maryland-clinic-now-countrys-biggest-babymaker/. 
Ditkowsky, Lisa. 2018. “White Paper: The Fertility Field Mergers & Acquisitions 
(M&A): Frothy or the Next Frontier?” Pllush Capital Management. August 
17, 2018. http://www.pllush.com/blog/fertility-ivf-donor-eggs-shady-grove-
fertility-centers-illinois-private-equ. 
Dorbian, Iris. 2016. “Lee Equity Partners Co-Launches New Fertility Company 
Prelude.” PE Hub (blog). October 17, 2016. 
https://www.pehub.com/2016/10/lee-equity-partners-co-launches-new-
fertility-company-prelude/. 
———. 2017. “Lee Equity-Backed Prelude Fertility Completes Vivere Health 
Acquisition.” PE Hub (blog). December 15, 2017. 
https://www.pehub.com/2017/12/lee-equity-backed-prelude-fertility-
completes-vivere-health-acquisition/. 




Dresner Partners. 2018. “Staying Ahead of the Curve: Healthcare - Women’s Health 
Sector.” Dresner Partners. June 2018. http://www.dresnerpartners.com/ace-
files/Fertility_June_2018.pdf. 
Ferla, Ruth La. 2018. “These Companies Really, Really, Really Want to Freeze Your 
Eggs.” The New York Times, September 6, 2018, sec. Style. 
https://www.nytimes.com/2018/08/29/style/egg-freezing-fertility-
millennials.html. 
Franklin, Sarah. 1997. Embodied Progress: A Cultural Account of Assisted 
Conception. London and New York: Routledge. 
———. 2006. “Embryonic Economies: The Double Reproductive Value of Stem 
Cells.” Biosocieties 1 (1): 71–90. 
———. 2013. Biological Relatives: IVF, Stem Cells, and the Future of Kinship. 
Durham: Duke University Press. 
Fraser, Nancy. 2015. “Legitimation Crisis? On the Political Contradictions of 
Financialized Capitalism.” Critical Historical Studies 2 (2): 157–89. 
https://doi.org/10.1086/683054. 
Fraser, Nancy, and Rahel Jaeggi. 2018. Capitalism: A Conversation in Critical 
Theory. Medford, MA: Polity Press. 
21 
 
GVR. 2019. “IVF Market Size Worth $36.2 Billion By 2026 | CAGR: 10.2%.” Grand 
View Research. March 2019. https://www.grandviewresearch.com/press-
release/global-ivf-market. 
Hawkins, Jim. 2009. “Doctors as Bankers: Evidence from Fertility Markets.” Tulane 
Law Review 84 (July): 841–98. 
———. 2013. “Selling ART: An Empirical Assessment of Advertising on Fertility 
Clinics’ Websites.” Indana Law Journal 88 (4): 1147–79. 
Helmreich, Stefan. 2008. “Species of Biocapital.” Science as Culture 17 (4): 463–78. 
https://doi.org/10.1080/09505430802519256. 
Ho, Catherine. 2017. “Private Equity-Backed Firm Acquires Majority of San 
Francisco’s Pacific Fertility Center.” SFGate. September 27, 2017. 
https://www.sfgate.com/business/article/Private-equity-backed-firm-acquires-
majority-of-12234717.php. 
Hogarth, Stuart. 2017. “Valley of the Unicorns: Consumer Genomics, Venture Capital 
and Digital Disruption.” New Genetics and Society 36 (3): 250–72. 
https://doi.org/10.1080/14636778.2017.1352469. 
Hogarth, Stuart, and Brian Salter. 2010. “Regenerative Medicine in Europe: Global 
Competition and Innovation Governance.” Regenerative Medicine 5 (6): 971–
85. https://doi.org/10.2217/rme.10.81. 
Jackson, Emily. 2017. “The Ambiguities of ‘Social’ Egg Freezing and the Challenges 
of Informed Consent.” BioSocieties, April, 1–20. 
https://doi.org/10.1057/s41292-017-0044-5. 
Jacoby, Melissa B. 2009. “The Debt Financing of Parenthood.” Law and 
Contemporary Problems 72 (3): 147–75. 
Kerr, Dara. 2017. “Egg Freezing, so Hot Right Now.” CNET. May 22, 2017. 
https://www.cnet.com/news/egg-freezing-so-hot-right-now/. 
Kindbody. 2018a. “Egg Freezing Facts.” Kindbody. 2018. https://kindbody.com/egg-
freezing-facts/. 
———. 2018b. “Kindbody Purchases Cloud-Based Software From IVFqc.” PR 
Newswire. August 4, 2018. https://www.prnewswire.com/news-
releases/kindbody-purchases-cloud-based-software-from-ivfqc-
300696756.html. 
———. 2019. “Kindbody - The Future of Women’s Health, Fertility and Wellness.” 
Kindbody. 2019. https://kindbody.com/. 
Krippner, Greta, Benjamin Lemoine, and Quentin Ravelli. 2017. “The Politics of 
Financialization.” Revue de La Régulation, no. 22 (December). 
https://doi.org/10.4000/regulation.12637. 
Kuwayama, Masashige, Gábor Vajta, Osamu Kato, and Stanley P. Leibo. 2005. 
“Highly Efficient Vitrification Method for Cryopreservation of Human 
Oocytes.” Reproductive BioMedicine Online 11 (3): 300–308. 
Lazzarato, Maurizio. 2012. The Making of the Indebted Man: An Essay on the 
Neoliberal Condition. Los Angeles, CA: Semiotexte. 
https://monoskop.org/images/6/62/Lazzarato_Maurizio_The_Making_of_the_
Indebted_Man_An_Essay_on_the_Neoliberal_Condition_2012.pdf. 
Lee, Bruce M. 2016. “Mercer Forms Strategic Alliance with Progyny.” Mercer. 
January 7, 2016. https://www.mercer.com/newsroom/mercer-progyny-
alliance.html. 
Market Cube. 2015. “Fertility Treatments in the United States: Sentiment, Costs and 





Martin, Lauren Jade. 2010. “Anticipating Infertility: Egg Freezing, Genetic 
Preservation, and Risk.” Gender & Society 24 (4): 526–45. 
https://doi.org/10.1177/0891243210377172. 
McLaughlin, J. E., J. F. Knudtson, R. S. Schenken, N. S. Ketchum, J. A. Gelfond, and 
R. D. Robinson. 2018. “Business Models and Provider Satisfaction in In-Vitro 
Fertilization Centers in the United States.” Fertility and Sterility 109 (3): e38. 
https://doi.org/10.1016/j.fertnstert.2018.02.073. 
Mercer. 2016. “Mercer Survey: Health Benefit Cost Growth Slows to 2.4% in 2016 as 
Enrollment in High-Deductible Plans Climbs.” Mercer. October 26, 2016. 
https://www.mercer.com/newsroom/national-survey-of-employer-sponsored-
health-plans-2016.html. 
Mulligan, Jessica. 2015. “Insurance Accounts: The Cultural Logics of Health Care 
Financing.” Medical Anthropology Quarterly 30 (1): 37–61. 
https://doi.org/10.1111/maq.12157. 
OVA. 2017. “New to Egg Freezing? The Top 10 Questions You Should Ask.” OVA 
Blog (blog). January 1, 2017. 
https://www.ovaeggfreezing.com/2017/01/01/new-to-egg-freezing-the-top-10-
questions-you-should-ask/. 
Ova. 2018. “Just in! OVA’s Laboratory Team Wins Again: Coveted Recognition of 
Excellence Award.” OVA. October 7, 2018. 
https://www.ovaeggfreezing.com/award-2018/. 
Prelude Fertility. 2017a. “Prelude Fertility.” Prelude Fertility, Inc. 2017. 
https://www.preludefertility.com/. 
———. 2017b. “Prelude Fertility Expands Network with Pacific Fertility Center in 
San Francisco.” PR Newswire. September 25, 2017. 
https://www.prnewswire.com/news-releases/prelude-fertility-expands-
network-with-pacific-fertility-center-in-san-francisco-300524534.html. 
Progyny. 2016. “Progyny to Present at 34th Annual J.P. Morgan Healthcare 
Conference.” PRWeb. January 8, 2016. 
http://www.prweb.com/releases/2016/01/prweb13155994.htm. 
———. 2019. “Progyny Welcomes 10 New Centers to Its Provider Network.” 
Progyny. January 2019. https://progyny.com/wp-
content/uploads/2019/01/Progyny_Q42018_ClinicAnnouncement.pdf. 
Robbins. 2017. “Investors See Big Money in Infertility. And They’re Transforming 
the Industry.” STAT. December 4, 2017. 
https://www.statnews.com/2017/12/04/infertility-industry-investment/. 
Rottenberg, Catherine. 2016. “Neoliberal Feminism and the Future of Human 
Capital.” Signs: Journal of Women in Culture and Society 42 (2): 329–48. 
https://doi.org/10.1086/688182. 
SART. 2019. “National Summary Report.” Society for Assisted Reproductive 
Technology. 2019. 
https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx. 
Silver-Greenberg, Jessica. 2012. “In Vitro a Fertile Niche for Lenders.” Wall Street 
Journal, February 24, 2012. 
https://www.wsj.com/articles/SB100014240529702039608045772412701232
49832. 
Strathern, Marilyn. 1990. “Enterprising Kinship: Consumer Choice and the New 
Reproductive Technologies.” Cambridge Anthropology 14 (1): 1–12. 
23 
 
Sunder Rajan, Kaushik. 2006. Biocapital: The Constitution of Postgenomic Life. 
Duke University Press. 
Van de Wiel, Lucy. Forthcoming. Freezing Fertility: Oocyte Cryopreservation and 
the Gender Politics of Ageing. New York: New York University Press. 
———. 2015. “Freezing in Anticipation: Eggs for Later.” Women’s Studies 
International Forum 53 (November-December): 119–28. 
https://doi.org/10.1016/j.wsif.2014.10.019. 
Varsavsky, Martin. 2016. “But Daddy, How Are Babies Made?” Martin Varsavky 
(blog). October 7, 2016. http://english.martinvarsavsky.net/paternity/but-
daddy-how-are-babies-made.html#comments. 
Vertommen, Sigrid. 2017. “From the Pergonal Project to Kadimastem: A Genealogy 
of Israel’s Reproductive-Industrial Complex.” BioSocieties 12 (2): 282–306. 
https://doi.org/10.1057/biosoc.2015.44. 
Waldby, Catherine. 2019. The Oocyte Economy: The Changing Meaning of Human 
Eggs. 1 edition. Durham: Duke University Press Books. 
Yang, Selena. 2018. “Progyny Ranks #3 on Crain’s Fast 50 2018 List.” Progyny. 
October 15, 2018. https://progyny.com/wp-
content/uploads/2018/10/CrainsFast50_10.15.18.pdf. 
 
 
 
 
 
